Aisha Hasan Image

Aisha Hasan

Partner

Barnes & Thornburg

Aisha R. Hasan is a partner in Barnes & Thornburg’s Raleigh office. She brings an expansive
background as a scientific researcher to her global patent law practice. Aisha’s passion for
creativity, particularly in the areas of immunology, molecular biology, and pharmaceuticals,
inspire her to clearly define and safeguard client assets when bringing innovation to markets
around the world.

Aisha focuses her practice on the preparing and prosecuting U.S. and foreign patent applications, as well all aspects of complex freedom-to-operate and due diligence reviews and IP transactions.

Aisha’s work spans a wide range of technical areas, including immunotherapies, biotechnology, small molecule pharmaceuticals, agricultural biotechnology, and diagnostic assays. Her clients include large agricultural chemical companies, pharmaceutical and biotech companies of varying size, as well as a variety of start-ups and emerging companies.

Prior to entering private practice, Aisha worked as a protein chemist at Trimeris Inc. on HIV and RSV research, as well as at the National Institutes of Health’s Laboratory of Structural Biology, where she studied the structure of natural killer cell receptors. Aisha is also skilled in clinical microbiology and virology, and chemical synthesis.

Recent Articles by Aisha Hasan

IP Audits for the Emerging Life Science Company: A Staged and Strategic Approach for Value

The trend is here to stay – large life science companies are basing their growth strategies on research and development happening at early-stage companies. It is easier, and less risky, for large companies simply to acquire these enterprises working on new and innovative therapeutic candidates that have advanced to a certain stage. For early stage life science companies (ESLSCs), intellectual property is the asset. Although 2021 saw what appeared to be a slowdown in deal-making activity compared to 2020, the top M&A and licensing deals were valued at well over $50 billion dollars. Whether to attract the attention of one of the larger players in the space – for a potential license or acquisition, to entice investors, or to remain competitive – a methodical and focused IP review should ensure clear alignment with business objectives and maximum return on investment. Not only does the IP audit provide the ESLSC a chance to broadly inventory and strategically review their IP, it also prepares them for any potential third-party diligence.